First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

/PRNewswire/ -- UCB, a global pharmaceutical company, today announced new 24-week data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, evaluating...

Related Keywords

United States ,Denmark ,Copenhagen ,Køavn ,United Kingdom ,Brussels ,Bruxelles Capitale ,Belgium ,Smyrna ,Izmir ,Turkey ,Emmanuel Caeymaex ,Musculoskelet Disord ,Eimear Obrien ,Antje Witte ,J Clin Pharmacol ,Immunology Solutions ,European Congress ,Brand Communications ,Twitter ,Ucb Inc ,Drug Administration ,Assessment Of Spondyloarthritis International Society ,Corporate Communications ,Source Ucb Inc ,Executive Vice President ,Spondyloarthritis International Society ,Open Label Extension ,Euronext Brussels ,Subjects With Active Ankylosing Spondylitis ,With Bimekizumab ,Patients With Active Ankylosing Spondylitis ,Results From ,Ann Rheum ,Long Term Safety ,Subjects With Ankylosing Spondylitis ,Axial Spondyloarthritis ,Active Psoriatic Arthritis ,Ucb ,Nc ,